Cardiac dysfunction in the trastuzumab clinical trials experience.

By A. Seidman, C. Hudis, M. K. Pierri, S. Shak, V. Paton, M. Ashby, M. Murphy, S. Stewart, D. Keefe. Journal of Clinical Oncology, 2002

1,545 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/d7caf98ffc6ced1ba36d07b03e4fb31ba721a80c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Oncology

Citations in the corpus

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, neutral): “The use of different LVEF cutoffs and methods of measurement (Teichholz, Simpson’s biplane, or area-lengthmethod) have compromised the ability to compare results from different studies and collect evidence-based data.(36,37) Although monitoring guidelines have been proposed for several potentially c”
Paul Ehrlich's magic bullet concept: 100 years of progress (2008, background): “For example, cardiotoxicity induced by trastuzumab results from the binding of this antibody to a receptor in heart tissue, and rituximab is associated with toxicity due to its binding normal B cells expressing CD20 (Ref”
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. (2010, background): “The incidence of trastuzumab-induced cardiotoxicity (TIC) varies according to the definition used in different studies but has been reported to be as high as 34% when associated with anthracyclines.(2,5-8) Trastuzumab causes a form of cardiotoxicity different from that typical of anthracyclines.”
Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab (2012, methodology): “The primary end point was the occurrence of cardiotoxicity as defined by the Cardiac Review and Evaluation Committee of trastuzumab-associated cardiotoxicity (CREC), that is, either a cardiomyopathy with decreased LVEF, a reduction of LVEF ≥5% to <55% with symptoms of heart failure (diagnosed by a c”
Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. (2014, methodology): “First, the measurement of LVEF is subject to technique-related variability, which can be higher than the thresholds used to define cardiotoxicity (8,10).”
ErbB receptors: directing key signaling networks throughout life. (2004, background): “risk of cardiac side effects, including cardiac dysfunction (126, 127).”
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “Generally, if there is a reduction in LVEF of 10 points, and especially if the number is below the institutional lower limit of normal (LLN) (or LVEF <50%), this is considered potential evidence of cardiotoxicity.(116) Exact definitions of cardiotoxicity have varied over the decades; if other compon”
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity (2004, background): “Treatment response was even less impressive in heavily pretreated patients who received trastuzumab single agent, but this refractoriness might well be attributed to reduced performance and functional capacity due to more advanced disease (Seidman et al., 2002; Perez and Rodeheffer, 2004).”
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition (2007, background): “The incidence of cardiac dysfunction ranged from 4% to 7% with trastuzumab alone, to 27% when chemotherapy that included anthracyclines was administered concurrentl”
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, methodology): “The use of different LVEF cut-offs and methods of measurement (Teichholz, Simpson’s biplane, or area-length method) have compromised the ability to compare results from different studies and collect evidence-based data.(36,37) Although monitoring guidelines have been proposed for several potentially”